Full text is available at the source.
Augmentation of Pharmacotherapy by Sleep Deprivation with Sleep Phase Advance in Treatment-Resistant Depression
Improving medication effects in hard-to-treat depression using sleep deprivation combined with earlier sleep timing
AI simplified
Abstract
Ten out of 21 participants showed a response to treatment with a reduction of ≥50% in depression symptoms by day 14.
- Total sleep deprivation (TSD) combined with sleep phase advance (SPA) may enhance the effects of existing antidepressant treatments in patients with treatment-resistant depression (TRD).
- Responders had lower baseline cortisol levels compared to non-responders, suggesting a potential association between cortisol and treatment response.
- Cortisol levels decreased during the treatment period in both responders and non-responders.
- An increase in the levels of interleukin-10 (IL-10) and IL-1β was observed in responders by day 14, indicating a possible link between these biochemical markers and clinical improvement.
AI simplified